Botensilimab
Resectable MMR-deficient Solid Tumors
The Netherlands Cancer Institutemonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Resectable MMR-deficient Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel The Netherlands Cancer Institute | Phase 2/3 | B |
Balstilimab The Netherlands Cancer Institute | Phase 2/3 | B |
Eloxatin The Netherlands Cancer Institute | Phase 2/3 | B |
FLUOROURACILUM The Netherlands Cancer Institute | Phase 2/3 | B |
Calcium folinate pentahydrate The Netherlands Cancer Institute | Phase 2/3 | B |
Same molecule, other indications
Botensilimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →